Health Economics Model Shows Cervarix(R) Cross-Protective Efficacy Could Provide Greater Cost Reductions Than Protection Against Genital Warts

Results from a modelling study have showed that cross-protective efficacy of GlaxoSmithKline’s Cervarix® against cervical cancer-causing human papillomavirus (HPV) types1,2 could provide greater public health cost reductions than the cost reductions potentially offered by Gardasil® due to its efficacy against Genital Warts.

Source: Health Economics Model Shows Cervarix(R) Cross-Protective Efficacy Could Provide Greater Cost Reductions Than Protection Against Genital Warts